Completed PHASE2 INTERVENTIONAL 1-arm NCT00569387

Vaccine Study for Surgically Resected Pancreatic Cancer

A Phase II Study of Algenpantucel-L (HyperAcute Pancreas) Cancer Vaccine in Subjects With Surgically Resected Pancreatic Cancer

Sponsor: NewLink Genetics Corporation

Conditions Pancreatic Cancer

Interventions HyperAcute(R)-Pancreatic Cancer Vaccine

Updated 8 times since 2017 Last updated: May 26, 2020 Started: Dec 31, 2007 Primary completion: Mar 31, 2011 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00569387, this PHASE2 trial focuses on Pancreatic Cancer and remains completed. Sponsored by NewLink Genetics Corporation, it has been updated 8 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2
Jun 2020 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jun 2020 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

NewLink Genetics Corporation

Data source: Lumos Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Aurora, United States , Burlington, United States , Chicago, United States , Cleveland, United States , Evanston, United States , Houston, United States , Indianapolis, United States , Los Angeles, United States , Miami, United States and 7 more locations